Recent Quotes (30 days)

You have no recent quotes
chg | %

Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for RVX
1.30
-0.04 (-2.99%)
May 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.27 - 1.30
52 week 1.00 - 2.68
Open 1.29
Vol / Avg. 4,100.00/19,103.00
Mkt cap 142.70M
P/E     -
Div/yield     -
EPS -0.42
Shares 105.20M
Beta 1.42
Inst. own     -
Mar 15, 2016
Resverlogix Corp at ROTH Conference
  

Key stats and ratios

Q1 (Jan '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -77.88% -151.54%
Return on average equity - -
Employees 19 -
CDP Score - -

Address

4820 Richard Rd SW Suite 300
CALGARY, AB T3E 6L1
Canada
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)

Website links

Description

Resverlogix Corp. is a clinical-stage cardiovascular company. The Company is developing small molecules that selectively inhibit Bromodomain and ExtraTerminal domain (BET) proteins. Its lead drug compound is RVX-208 (apabetalone). RVX-208 is a small molecule targeted for the treatment of atherosclerosis via the reduction of major adverse cardiovascular events (MACE), and also for treatment of diabetes mellitus (DM), chronic kidney disease (CKD) and Alzheimer's disease (AD). RVX-208 is an oral agent in the BET inhibitor class that targets bromodomain 2 (BD2) of BET protein4 (BRD4) by regulating gene activities. RVX-208 has anti-inflammatory effects, including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, complement, factors involved in atherosclerosis and vascular risk. The Company has initiated a Phase III clinical trial BETonMACE with RVX-208 for cardiovascular disease patients with DM and low high-density lipoprotein (HDL).

Officers and directors

Donald J. McCaffrey Chairman of the Board, President, Chief Executive Officer, Secretary
A. Brad Cann CA Chief Financial Officer
Jan O. Johansson M.D., Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Michael T. Sweeney M.D. Senior Vice President - Clinical Development
Norman Wong M.D. Chief Scientific Officer
Eldon R. Smith M.D. Lead Director
Age: 75
Norma K. Biln Director
Shawn Lu Director
Kelly B. McNeill Independent Director